Next Article in Journal
IAmHero: Preliminary Findings of an Experimental Study to Evaluate the Statistical Significance of an Intervention for ADHD Conducted through the Use of Serious Games in Virtual Reality
Previous Article in Journal
Risk Prediction for the Development of Hyperuricemia: Model Development Using an Occupational Health Examination Dataset
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 20
Issue 4
10.3390/ijerph20043413
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Effect of Neoglandin on the Activity of N-Acetyl-β-D-Hexosaminidase in the Serum and Urine of Alcohol-Dependent Men

by
Sławomir Dariusz Szajda
1,*,
Jacek Dobryniewski
2,
Alina Minarowska
3,
Jadwiga Snarska
4,
Napoleon Waszkiewicz
5 and
Krzysztof Zwierz
6
1
Department of Emergency Medical Service, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland
2
DJV Sp. z.o.o., 15-660 Bialystok, Poland
3
Department of Pulmonology Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-357 Olsztyn, Poland
4
Department of Surgery, Collegium Medicum University of Warmia and Mazury in Olsztyn, 10-228 Olsztyn, Poland
5
Department of Psychiatry, Medical University of Bialystok, 15-272 Bialystok, Poland
6
Academy of Applied Sciences in Lomza, 18-400 Lomza, Poland
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2023, 20(4), 3413; https://doi.org/10.3390/ijerph20043413
Submission received: 1 November 2022 / Revised: 3 February 2023 / Accepted: 6 February 2023 / Published: 15 February 2023
(This article belongs to the Section Toxicology and Public Health)
Browse Figures
Versions Notes

Abstract

:
Dietary supplementation of gamma-linolenic acid (GLA) in the form of a commercial drug neoglandin (containing GLA and vitamin E), in people following alcohol abuse allows bypassing of the ineffective delta-6-desaturase system involved in the transformation of linoleic acid into GLA. Determination of the activity of N-acetyl-β-D-hexosaminidase (HEX) in the serum and urine reflects neoglandin action on the catabolism of glycoconjugates and the functioning of liver and kidneys in people following alcohol abuse. Material and methods: The serum and urine were collected from men with alcohol dependence, treated (n = 31, age 33.16 ± 9.72 years) and not treated (n = 50, age 35.46 ± 11.37 years) with neoglandin. HEX activity were assayed in the supernatants by the colorimetric method, with the p-nitrophenyl derivative of sugar as substrate. Results: Our study on alcoholic men not treated with neoglandin indicates a significantly higher concentration of the serum and urinary HEX activity (nKat/L) on day 1 compared to days 7, 10, 14 and 30 (p < 0.001). For days 14 and 30 (p < 0.01), the urinary HEX activity was expressed in μKat/kgCr. No significant differences were observed in the activity of serum (nKat/L) and urinary (nKat/L and μKat/kgCr) HEX in alcoholics during treatment with neoglandin compared to day 1 of neoglandin treatment. We found significantly different (p < 0.05) concentration of HEX activity (nKat/L) in serum of alcohol-dependent men treated with neoglandin compared to those not taking neoglandin on days 7, 10, 14 and 30 of treatment. The urinary concentration of HEX activity (nKat/L) on days 1, 4, 10 and 30 and HEX activity in μKat/kgCr on days 1, 4 and 7 it was significantly higher (p < 0.05) during the treatment of alcohol-dependence without the use of neoglandin as compared to alcoholics treated with neoglandin. We found a positive correlation between the amount of alcohol consumed and the urinary activity of HEX in the early phase after alcohol withdrawal and a lack of correlation between the HEX activity in serum and urine of alcohol-dependent men not treated with neoglandin. Conclusions: Neoglandin supplementation in alcoholic men significantly slows down the catabolism of glycoconjugates, thus reducing the effects of ethanol poisoning that are harmful to the kidneys. Neoglandin reduces the harmful effects of ethanol poisoning more on the kidneys than on the liver. The activity of HEX in the serum may be used in monitoring the treatment of alcoholism and whether alcohol reuse occurred during the therapy. In the early stages of alcohol withdrawal, urinary HEX activity can be used as a marker of the amount of alcohol consumed during previous alcohol abuse.

1. Introduction

Alcohol and its metabolites interfere with the functioning of many human body organs, causing several diseases. Alcohol provides the human body with empty calories, disrupts the energy balance, and leads to nutritional deficiencies. The oxidation of ethanol in the liver by alcohol dehydrogenase results in the formation of toxic acetaldehyde with the production of NADH and the reduction of NAD/NADH. These processes lead to excessive fat accumulation in the liver; hence, hepatic steatosis is the first symptom of alcohol abuse [1,2,3].
In the chronic alcohol abuse, the second hepatic pathway of alcohol metabolism (MEOS) gains the upper hand, where cytochrome P 450 plays a key role. This pathway of metabolism, in addition to the additional potentiation of the conversion of alcohol to acetaldehyde, causes oxygen deficiency leading to cell and tissue damage and energy deficits, impaired fat and fatty acid metabolism and oxidative stress [4].
Acetaldehyde, on the other hand, leads to protein damage, impaired DNA repair and excessive collagen production [5].
There is an association between ethyl alcohol abuse and metabolic disorders of essential fatty acids (EFA). Chronic alcohol consumption provides the dependent person with about 50% of his or her caloric demand, which changes the metabolism of EFA [6]. Ingested ethanol inhibits the activity of delta-6-desaturase and delta-5-desaturase, which are key enzymes involved in the transformation of linoleic acid (LA) to longer chains of the unsaturated fatty acids gamma-linolenic acid (GLA) and dihomo-gamma-linolenic acid (DGLA), as well as arachidonic acid (AA) [6,7,8,9].
The delta-6-desaturase block of the ingested alcohol, causes a deficiency of essential fatty acids, resulting from blocking the conversion of essential unsaturated fatty acids (EUFA) at the level of transformation of linoleic acid to GLA and DGLA [10]. GLA supplementation with neoglandin (containing vitamin E) allows EUFA to bypass the ineffective delta-6-desaturase system while providing an increased amount of DGLA precursor. This produces AA and other important metabolites of EFA [10].
Current options for treating damage caused by alcohol and its metabolites in humans are very limited. The positive effect of polyunsaturated fatty acids and vitamin E on liver damage caused by alcohol and free radicals has been evaluated [11,12,13].
There are also reports that GLA has a positive effect on the treatment of atopic dermatitis, age-related diseases, diabetic neuropathy, and alcohol dependence [14].
Currently, self-assessment questionnaires and biological markers are used in the diagnosis of alcoholism. The limitation of self-assessment questionnaires is due to non-disclosure of alcoholism by the patient in clinical settings and additional stress during the study [15]. Alcohol abuse biological markers include gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), mean corpuscular volume (MCV), and the low-carbohydrate isoform of transferrin (CDT), or desialated transferrin. The concentrations of these biological markers in blood serum correlates with the intensity of alcohol consumption. However, biological markers are characterized by too low sensitivity and specificity to be treated as reliable tests. Biological markers are useful for general clinical evaluation and may suggest the existence of alcoholism [16].
In addition to these markers of alcoholism, changes in the activity of N-acetyl-β-hexosaminidase (HEX) in serum, urine, and saliva [17,18,19] should be considered as an indicator. HEX is the most active of lysosomal exoglycosidases, hydrolyzing N-acetylglucosamine and N-acetyl galactosamine residues from the non-reducing ends of the oligosaccharide chains of glycoproteins, glycolipids, and proteoglycans, collectively referred to as glyconjugates [20]. HEX activity in serum and urine correlates with the duration and amount of ethanol consumption and is a sensitive indicator of ethyl alcohol abuse [19].
The aim of our study was to assess the effect of neoglandin (borage oil, GLA, and vitamin E) treatment on the activity of HEX in the serum and urine of patients hospitalized due to long-term alcoholism.

2. Materials and Methods

The study group consisted of 31 men aged 20–56 years (mean 33.16 ± 9.72 years) hospitalized after long-lasting alcoholism at the Detoxification Wards and the Alcohol Dependence Therapy Unit at SPPZOZ in Choroszcz, Poland. The men received threeneoglandin capsules (369 mg borage seed oil, polyunsaturated essential fatty acids 203 mg, gamma-linolenic acid (GLA) 74 mg, vitamin E 1.0 mg) twice daily in addition to the standard treatment starting from the first day of their hospitalization. The patients of the study met the alcohol dependence criteria by ICD-10 classification and were admitted to the hospital directly after alcohol abuse for detoxification and further treatment of alcohol dependence. The length of time when alcohol was abused ranged from 4 to 90 days (average 23.74 ±17.60 days). The declared daily intake of alcohol calculated as 100% ethanol was from 80 to 400 g (average 219.68 ± 87.65 g).
The control group consisted of patients hospitalized in the same departments and for the same indications as in the study group. Patients of the control group underwent only standard treatment, without further neoglandin treatment. The control group consisted of 50 men aged 20–67 years (mean 35.46 ± 11.37 years). The control group patients were admitted to the ward after a recent excessive alcohol consumption lasting from 4 to 180 days (mean 28.58 ± 33.27 days). The amount of alcohol consumed calculated per 100% ethanol was 80 to 800 g (average 317.0 ± 168.71 g).
Patients disqualified from the study included those with non-ethanol addiction disorders that may be associated with increased NAG activity in the urine e.g., severe non-alcoholic liver disease, myocardial infarction, hypertension, diabetes, sepsis, kidney diseases, urinary tract infections, and thyrotoxicosis. Serum and urine samples were collected on days 1, 4, 7, 10, 14 and 30 of abstinence from alcohol. During hospitalization, patients were intravenously administered 5% glucose, multi-electrolyte fluid, and 0.9% NaCl. They were also intramuscularly or orally administered haloperidol (up to 20 mg/day), diazepam (up to 50 mg/day), and B-group vitamins.
Blood was collected on an empty stomach. The collection was made from the elbow vein at a fixed time—in the morning. Urine samples were collected on the first morning of hospitalization from the middle stream. Blood (after clotting) and urine were centrifuged for 20 min at 3.000 rpm, divided into aliquots, and stored in Eppendorf plastic tubes at −86 °C until the assays were made.
HEX activity in the serum and urine was determined by the Chatterjee et al. method [21] modified by Zwierz et al. [22]. To 50 µL of the serum and urine samples to be tested was added 200 µL of 0.1 M phosphate-citrate buffer at pH 4.7, and 150 µL of 20 mM substrate solution of p-Nitrophenyl-N-acetyl-β-D-glucosaminide (Sigma, St. Louis, MO, USA), and then incubated for 60 min in a warmbath at 37 °C. The reaction was stopped by adding 1 mL of 0.2 M borate buffer, at pH 9.8, to the incubated solution. The activity HEX, corresponding to the amounts of released p-nitrophenol, were measured at 410 nm, using a Specol spectrophotometer. The amount of p-nitrophenol released in the reaction was read from the calibration plot. Creatinine concentration was determined by the kinetic method [23] using the Mascott Lisa Plus analyzer (Hycel Diagnostic, Massy, France).
The study was carried out with the approval of the Bioethical Commission of the Medical University of Bialystok.
In statistical analysis, the normality of distribution was verified by Kolmogorov–Smirnov tests with the Lilliefors correction and the Shapiro-Wilk test. A normal distribution of the analyzed quantitative variables was not produced. Because the quantitative variables did not produce a normal distribution, the non-parametric Mann–Whitney U test was used for the two groups. For the dependent variables, the Friedman ANOVA test was used with the adjusted post hoc Conover test. The Spearman rank correlation coefficient was also determined. Statistically significant results were found at p < 0.05. The Statistica 10.0 package from StatSoft and PASW Statistics 17.0 from Predictive Solutions were used for the calculations.

3. Results

The conducted studies suggest that in the serum of male alcoholics not treated with neoglandin, the concentration of HEX activity (nKat/L) was significantly higher (p < 0.001) on day 1 compared to days 7, 10, 14 and 30 of treatment (Figure 1). In the serum of neoglandin-treated alcoholics, there were no significant differences in HEX activity concentration (nKat/L) on days 4, 7, 10, 14, 30, compared to day 1 of treatment for alcohol dependence with neoglandin (Figure 2). Significantly higher (p < 0.05) concentration of HEX activity (nKat/L) was found in the serum of alcohol-dependent men treated with neoglandin compared to those who did not take neoglandin on days 7, 10, 14 and 30 of treatment (Table 1, Figure 3).
In the urine of alcoholic men not taking neoglandin, the concentration of the HEX activity (nKat/L) was significantly higher (p < 0.001) on day 1 compared to days 7, 10, 14 and 30 of treatment (Figure 4). Found no significant differences in HEX activity concentration (nKat/L) in the urine on days 4, 7, 10, 14, 30, compared to day 1 of treatment for alcohol dependence with neoglandin (Figure 5). Significantly higher (p < 0.05) concentration of HEX activity (nKat/L) were found in the urine of alcohol-dependent men not treated with neoglandin compared to those taking neoglandin on days 1, 4, 10 and 30 of treatment (Table 2 and Figure 6). In the urine of alcoholic men not taking neoglandin, the concentration of HEX activity calculated per kg creatinine (μKat/kgCr) was significantly higher (p < 0.01) on day 1 compared to day 14 and 30 of treatment (Figure 7). No significant differences in the concentration of HEX activity per kg of creatinine (μKat/kgCr) in the urine were found on days 4, 7, 10, 14, 30 compared to day 1 of treatment for alcohol-dependence with neoglandin (Figure 8). A significantly higher (p < 0.05) concentration of HEX activity after the conversion to kg of creatinine (μKat/kgCr) was found in the urine of men with alcohol-dependence without neoglandin treatment, as compared to those taking neoglandin on days 1, 4, and 7 of treatment (Table 3 and Figure 9).
There appears to be a positive correlation between the amount of alcohol consumed and the activity of HEX in the urine in the early phase of alcohol withdrawal, which suggests the possibility of using HEX as a marker of the amount of alcohol consumed (Table 4).

4. Discussion

HEX activity has been demonstrated in many tissues and organs: kidney, spleen, liver, gastric and intestinal mucosa, cerebral cortex, skin fibroblasts, placenta, and cancerous tissues. This enzyme has also been detected in biological fluids such as serum, urine, cerebrospinal fluid, and synovial fluid [24].
Ethanol and its metabolites: acetic aldehyde, free radicals, and fatty acid ethyl esters, as well as the ethanol-water competition mechanism, disturb the processes of glycoconjugate metabolism (biosynthesis, modification, transport, secretion, elimination and catabolism) [25]. Since most ingested alcohol and most plasma glycoproteins are metabolized in the liver, the two processes interfere with each other, resulting in impaired metabolism of the glycoconjugates.
Previous studies indicated the increasing activity of HEX in alcoholics. The average HEX levels were twice as high in alcoholics after drinking alcohol compared to the so-called social drinkers and total abstainers. The sensitivity of HEX in detecting heavy drinking, defined as 60 g of pure ethanol per day, was 85.7% compared to 47.6% for GGT. Positive correlations between HEX and AST (r = 0.74, p < 0.0001) and ALT (r = 0.41, p < 0.05) [24] indicate that elevated HEX levels may reflect early liver damage. Plasma HEX seems to be a sensitive biological marker of heavy drinking, better reflecting the amount of ethanol ingested than GGT [24].
Our study shows that in the serum of male alcoholics not treated with neoglandin the concentration of HEX activity (nKat/L) was significantly higher (p < 0.001) on day 1 compared to days 7, 10, 14 and 30 of treatment (Figure 1). In the group of men not treated with neoglandin, the concentration of HEX activity decreased significantly over time, and on day 30 of treatment, it was more than one and a half times lower compared to day 1 of treatment, reaching values referred to as normal [24,26] (Table 1).
The obtained results are consistent with the studies of other authors [24,26,27], in which they showed that in people addicted to alcohol, after several days of drinking, the activity of plasma HEX on the first day of abstinence was significantly higher than the activity of HEX determined in the group of people drinking socially or abstinent. The study of the concentration of HEX activity in the serum of alcohol-dependent men treated with neoglandin suggests no significant differences in HEX activity between individual days of blood collection (Figure 2). In the serum of men taking neoglandin, we did not observe the expected faster decrease in HEX activity compared to men not taking neoglandin. On the other hand, increased HEX activity in the serum of men addicted to alcohol was found up to 30 days of neoglandin therapy, which suggests that neoglandin as a whole or one of its components supports increased catabolism of glycoconjugates in lysosomes and contributes to high HEX activity.
Comparing the concentrations of HEX activity in the serum of men addicted to alcohol not treated with and treated with neoglandin, significantly lower HEX activity was found on days: 7 (p < 0.05), 10 (p < 0.01), 14 (p < 0.01) and 30 (p < 0.001) in untreated versus neoglandin-treated men (Table 1 and Figure 3). The difference in the concentration of HEX activity was on average about 30% in favor of the group receiving the neoglandin preparation. These results suggest that the neoglandin preparation stimulates the lysosomal catabolism of HEX containing glycoconjugates.
It seems that the reason for the increased activity of HEX in the serum of men addicted to alcohol and treated with neoglandin may be borage oil, which increases the level of DGLA, causing an increase in the level of prostaglandins of the 1 series, e.g., PGE 1, which, like other prostaglandins, is involved in the inflammatory process, causing redness, swelling, pain, increased temperature, and partial or complete loss of function of a given organ. However, the effect of PGE 1 on segmented nucleated leukocytes is mainly inhibitory [28]. PGE1 increases the concentration of intracellular cyclic AMP (cAMP), which in turn reduces the release of lysosomal enzymes, the chemotaxis of polymorphonuclear leukocytes and the margination and adhesion of leukocytes in blood vessels. It is also believed that PGE1 inhibits the activity of lymphocytes [29]. Exogenous PGE1 inhibits both lymphocyte function in vitro and lymphocyte-mediated reactions in vivo. There is an opinion that PGE1 initially promotes the formation of the inflammatory process to inhibit inflammation at a later stage. Bonta and Pernham [30] showed that PGE1 administered to rats fed a diet devoid of EFA (producing meagre amounts of prostaglandins) induced a pro-inflammatory effect during the first ten days of the experiment through dilatation and increased permeability of vessels, which resulted in increased migration of granulocytes, which effect was gradually replaced by the opposite effect—anti-inflammatory effect induced by cAMP.
The obtained results may suggest that neoglandin as a whole or some of its components, such as, e.g., borage oil, stimulates the lysosomal catabolism of glycoconjugates through its pro-inflammatory effect. In the next series of experiments, it is worth examining the effect of the individual components of the neoglandin preparation on the activity of serum HEX and other indicators of chronic consumption of excessive amounts of ethanol.
In order to assess whether neoglandin has a positive or negative effect on the metabolism of glycoconjugates, it would be necessary to study not only the effect of neoglandin on the breakdown of glycoconjugates, e.g., by determining HEX activity, but also the effect of neoglandin on the rate of biosynthesis of glycoconjugates.
Determination of urinary enzyme activities is a sensitive and non-invasive method for assessing renal tubular function. Out of more than 50 enzymes produced in the epithelium of the proximal renal tubules and secreted to urine, only several have found application in medical diagnostics [31].
HEX is a recognized, useful, low-cost marker for assessing proximal renal tubular function. Increased HEX secretion into the urine is observed in acute and chronic glomerulonephritis and after poisoning with heavy metal salts. Determining HEX in urine has found application in monitoring of drug nephrotoxicity and renal status after transplantation [31].
Proteins with a molecular weight greater than 68 kD [32] do not pass through renal glomeruli, and HEX is not filtered through a properly functioning renal tubular membrane filter. Nevertheless, low HEX activity was observed in the urine of healthy people, which indicates that the breakdown of the renal cells and damage to the membranes results in the release of HEX into the urine. The reason for the presence of HEX in physiological urine may be that under normal cell metabolism, the lysosomal enzymes can be released out of the cell and into the urine [33].
After analysis of the concentration of HEX activity (nKat/L) in the urine of alcoholic men not treated with neoglandin, we found a significant decrease in HEX activity (p < 0.001) in days 7, 10, 14, and 30 of treatment as compared to day 1 of treatment (Figure 4). The study shows that the concentration of HEX (nKat/L) activity in the urine of alcoholic men supplemented with neoglandin decreased over time. On day 30 of the neoglandin treatment, the concentration of urinary HEX activity (Table 2 and Figure 5) was similar to the concentration of urinary HEX activity observed in healthy people [34].
Our study on the concentration of the urinary HEX (nKat/L) activity in alcoholic men treated with neoglandin indicates no significant changes in HEX activity during treatment with neoglandin (Figure 5).
Upon comparing the levels of HEX activity in the urine of alcoholic men, we observed significantly lower HEX activity on days 1 (p < 0.001), 4 (p < 0.01), 10 (p < 0.05) and 30 (p < 0.05), in men treated versus those not treated with neoglandin (Table 2 and Figure 6).
Positive results of neoglandin treatment on HEX activity in the urine of alcoholic men have been observed since the beginning of neoglandin treatment for alcohol-dependence (Table 2 and Figure 5). The difference in concentration of HEX (nKat/L) activity between the alcoholic men treated and not treated with neoglandin was, on average, 30% in favor of men taking neoglandin. In this group, the HEX (nKat/L) activity in urine was lower than in the urine of men not treated with neoglandin. Our results suggest that the neoglandin treatment positively impacts the kidneys, reducing the harmful effects of the consumed ethanol’s nephrotoxic action.
It has been reported that urinary creatinine concentration depends directly on muscle mass and magnitude of renal excretion and significantly decreases during fasting and acute and chronic renal failure [35]. It is accepted that the best way to eliminate the effect of diuresis on HEX concentration and HEX activity in urine is to compare HEX activity to urine creatinine. Calculation of urinary HEX activity on creatinine excludes the influence of individual variations on the urinary activity of HEX [36]. Our study found that 30-day neoglandin therapy did not significantly affect renal excretion of creatinine compared to alcohol-dependent males who were not treated with neoglandin. Therefore, the results of urinary HEX activity calculated per 1 kg of creatinine (Table 3 and Figure 7, Figure 8 and Figure 9) seemed to be valuable, as it indicated a significant decrease in urinary HEX activity on day 14 (p < 0.01) and 30 (p < 0.001) of treatment of alcoholic men not treated with neoglandin as compared to day 1 of treatment (Figure 7).
The concentration of urinary HEX activity calculated per 1 kg of creatinine (μKat/kgCr) indicated no significant differences in urinary HEX activity on particular days of neoglandin treatment as compared to day 1 of neoglandin treatment (Figure 8). The comparison of urinary HEX activity calculated per 1 kg of creatinine (μKat/kgCr) indicated a significantly higher urinary HEX activity for men not treated with neoglandin compared to those treated with neoglandin on days 1 (p < 0.05), 4 (p < 0. 01) and 7 (p < 0.05), and the absence of significant growth of urinary HEX activity on days 10, 14 and 30 (Table 3 and Figure 9). The reduction in urinary concentration of HEX activity (nKat/L) and urinary HEX activity calculated per 1 kg of creatinine (μKat/kgCr) in the following days, as compared to the first day of neoglandin treatment (Table 2 and Table 3), may indicate that the toxic effects of alcohol do not cause permanent kidney damage in alcoholic men. In our study, it seems significant that the HEX activity values in the urine of men treated with neoglandin remained at normal levels. This may suggest that neoglandin supplementation has a positive effect on the kidneys.
Based on our urinary HEX study, it can be concluded that neoglandin reduces the harmful effects of ethanol poisoning on the kidneys because neoglandin supplementation significantly reduces the urinary HEX activity of alcoholic men compared to alcoholic men not treated with neoglandin.
A positive correlation between the amount of alcohol consumed by alcoholic men and the urinary HEX activity in the early phase of alcohol withdrawal suggests that HEX could serve as a marker for measuring of alcohol consumption (Table 4).
The lack of correlation between the concentration of HEX activity in serum and urine and the concentration of HEX activity in serum and the HEX activity calculated per 1 kg of creatinine in the urine suggests that the HEX activity in the urine of alcohol-dependent men not treated with neoglandin does not depend on the HEX activity in the serum, which may be due to the toxic effects of alcohol on the kidneys.

5. Conclusions

  • Long-term alcohol abuse and diet supplementation with neoglandin slow down the catabolism of glycoconjugates.
  • Neoglandin reduces the harmful effects of ethanol poisoning more on the kidneys than on the liver.
  • The concentration of HEX activity in the serum may be used in monitoring the treatment of alcoholism and whether alcohol reuse occurred during the therapy.
  • The concentration of urinary HEX activity of alcoholic men in the early phase of alcohol withdrawal may be used as a marker for measuring alcohol consumption.
  • Determination of the concentration of serum and urinary HEX activity is a cheap and easy method for diagnosing alcohol addiction.

Author Contributions

Conceptualization, S.D.S., J.D., N.W. and K.Z.; methodology, J.D. and K.Z.; software, J.D.; validation, N.W. and K.Z.; formal analysis, S.D.S. and K.Z.; investigation, N.W.; resources, J.D. and K.Z.; data curation, J.D.; writing—original draft preparation, S.D.S., A.M., J.S. and K.Z.; writing—review and editing, S.D.S., A.M., J.S. and K.Z.; visualization, S.D.S., J.D., A.M., J.S. and K.Z.; supervision, N.W. and K.Z.; project administration, S.D.S., N.W. and K.Z.; funding acquisition, A.M. and J.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Local Ethic Committee R-I003/49/2003.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data supporting reported results can be obtained from the corresponding author on request.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study, in the collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. Author Jacek Dobryniewski was employed by the company DJV Sp. z.o.o. The all authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Lieber, C.S. Alcohol, liver, and nutrition. J. Am. Coll. Nutr. 1991, 10, 602–632. Available online: https://pubmed.ncbi.nlm.nih.gov/1770192/ (accessed on 10 October 2022). [CrossRef]
  2. Lieber, C.S.; Schmid, R. The effect of ethanol on fatty acid metabolism; stimulation of hepatic fatty acid synthesis in vitro. J. Clin. Investig. 1961, 40, 394–399. Available online: https://pubmed.ncbi.nlm.nih.gov/13761991/ (accessed on 10 October 2022). [CrossRef]
  3. Lieber, C.S.; Schmid, R. Stimulation of hepatic fatty acid synthesis by ethanol. Am. J. Clin. Nutr. 1961, 9, 436–438. Available online: https://pubmed.ncbi.nlm.nih.gov/13761990/ (accessed on 10 October 2022). [CrossRef] [PubMed]
  4. Tsutsumi, M.; Lasker, J.M.; Shimizu, M.; Rosman, A.S.; Lieber, C.S. The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology 1989, 10, 437–446. Available online: https://pubmed.ncbi.nlm.nih.gov/2673969/ (accessed on 10 October 2022). [CrossRef] [PubMed]
  5. Yokoyama, H.; Nagata, S.; Moriya, S.; Kato, S.; Ito, T.; Kamegaya, K.; Ishii, H. Hepatic fibrosis produced in guinea pigs by chronic ethanol administration and immunization with acetaldehyde adducts. Hepatology 1995, 21, 1438–1442. Available online: https://pubmed.ncbi.nlm.nih.gov/7737650/ (accessed on 10 October 2022). [PubMed]
  6. Dobryniewski, J.; Szajda, S.D.; Waszkiewicz, N.; Zwierz, K. Biology of essential unsaturated fatty acids. Przegl. Lek. 2007, 64, 91–99. Available online: https://pubmed.ncbi.nlm.nih.gov/17892040/ (accessed on 10 October 2022). [PubMed]
  7. Horrobin, D.F. Gamma linolenic acid: An intermediate in essential fatty acid metabolism with potential as an ethical pharmaceutical and as a food. Rev. Contemp. Physiol. 1990, 1, 1–41. [Google Scholar]
  8. Horrobin, D.F. Essential fatty acids, prostaglandins, and alcoholism: An overview. Alcohol. Clin. Exp. Res. 1987, 11, 2–9. Available online: https://pubmed.ncbi.nlm.nih.gov/3032012/ (accessed on 10 October 2022). [CrossRef] [PubMed]
  9. Horrobin, D.F. Interactions between n-3 and n-6 essential fatty acids (EFAs) in the regulation of cardiovascular disorders and inflammation. Prostaglandins Leukot. Essent. Fatty Acids 1991, 44, 127–131. Available online: https://pubmed.ncbi.nlm.nih.gov/1745654/ (accessed on 10 October 2022). [CrossRef]
  10. Horrobin, D.F. A biochemical basis for alcoholism and alcohol-induced damage including the fetal alcohol syndrome and cirrhosis: Interference with essential fatty acid and prostaglandin metabolism. Med. Hypotheses 1980, 6, 929–942. Available online: https://pubmed.ncbi.nlm.nih.gov/6253773/ (accessed on 10 October 2022). [CrossRef]
  11. Tanaka, T.; Goto, Y.; Imano, M.; Asai, H.; Yamada, T.; Kawai, S.; Kunitoh, S.; Kondo, K.; Yamashita, T.; Monna, T.; et al. Effect of vitamin E deficiency on inhibition of liver regeneration by long-term administration of alcohol. Alcohol. Clin. Exp. Res. 1996, 20 (Suppl. S1), 47A–50A. Available online: https://pubmed.ncbi.nlm.nih.gov/8659689/ (accessed on 10 October 2022).
  12. Waszkiewicz, N.; Szajda, S.D.; Waszkiewicz, M.; Knaś, M.; Borzym-Kluczyk, M.; Dobryniewski, J.; Dutkiewicz, E.; Zwierz, P.; Zwierz, K. Silymarin in treatment of liver diseases. Med. Sci. Rev. Hepatol. 2006, 6, 92–98. Available online: https://journals.indexcopernicus.com/search/article?articleId=402270 (accessed on 10 October 2022).
  13. Wang, X.; Quinn, P.J. Vitamin E and its function in membranes. Prog. Lipid Res. 1999, 38, 309–336. Available online: https://pubmed.ncbi.nlm.nih.gov/10793887/ (accessed on 10 October 2022). [CrossRef]
  14. Dobryniewski, J.; Szajda, S.D.; Waszkiewicz, N.; Zwierz, K. Gamma linolenic acid (GLA)- therapeutical importance. Przegl. Lek. 2007, 64, 100–102. Available online: https://pubmed.ncbi.nlm.nih.gov/17892041/ (accessed on 10 October 2022).
  15. Waszkiewicz, N.; Szajda, S.D.; Kepka, A.; Szulc, A.; Zwierz, K. Glycoconjugates in the detection of alcohol abuse. Biochem. Soc. Trans. 2011, 39, 365–369. Available online: https://pubmed.ncbi.nlm.nih.gov/21265805/ (accessed on 10 October 2022). [CrossRef] [PubMed]
  16. Waszkiewicz, N.; Konarzewska, B.; Waszkiewicz, M.; Poplawska, R.; Szajda, S.D.; Zalewska, A.; Markowski, T.; Szulc, A. Biomarkers of alcoholabuse. Part I. Traditional biomarkers and its interpretation. Psychiatr. Pol. 2010, 44, 127–136. Available online: https://pubmed.ncbi.nlm.nih.gov/20449986/ (accessed on 10 October 2022). [PubMed]
  17. Zaniewska, A.; Borzym-Kluczyk, M.; Szajda, S.D.; Romatowski, J.; Gil, A.; Knas, M.; Dobryniewski, J.; Zwierz, K. The activity of lysosomal exoglycosidases in serum of alcohol-dependent men supplemented with borage oil enriched with vitamin E. J. Med. Food 2009, 12, 914–918. Available online: https://pubmed.ncbi.nlm.nih.gov/19735195/ (accessed on 10 October 2022). [CrossRef]
  18. Waszkiewicz, N.; Kratz, E.M.; Chojnowska, S.; Zalewska, A.; Zwierz, K.; Szulc, A.; Szajda, S.D.; Nestsiarovich, A.; Kapitau, A.; Kępka, A.; et al. Long-term changesof salivary exoglycosidases and their applicability as chronic alcohol-drinking and dependence markers. World J. Biol. Psychiatry 2019, 20, 64–75. Available online: https://pubmed.ncbi.nlm.nih.gov/28660791/ (accessed on 10 October 2022). [CrossRef]
  19. Waszkiewicz, N.; Popławska, R.; Konarzewska, B.; Szajda, S.D.; Galińska, B.; Rutkowski, P.; Leśniak, R.; Szulc, A. Biomarkers of alcoholabuse. Part II. New biomarkers and its interpretatio. Psychiatr. Pol. 2010, 44, 137–146. Available online: https://pubmed.ncbi.nlm.nih.gov/20449987/ (accessed on 10 October 2022). [PubMed]
  20. Zwierz, K.; Zalewska, A.; Zoch-Zwierz, A. Isoenzymes of N-acetyl-beta-hexosaminidase. Acta Biochim. Pol. 1999, 46, 739–751. Available online: https://pubmed.ncbi.nlm.nih.gov/10698282/ (accessed on 10 October 2022). [CrossRef] [PubMed]
  21. Chatterjee, S.; Velicer, L.F.; Sweeley, C.C. Glycosphingolipid glycosyl hydrolases and glycosidases of synchronized human KB cells. J. Biol. Chem. 1975, 250, 4972–4979. Available online: https://pubmed.ncbi.nlm.nih.gov/1150649/ (accessed on 10 October 2022). [CrossRef]
  22. Zwierz, K.; Gindzienski, A.; Ostrowska, L.; Stankiewicz-Choroszucha, B. Metabolism of glycoconjugates in human gastric mucosa a review. Acta. Med. Hung. 1989, 46, 275–288. Available online: https://pubmed.ncbi.nlm.nih.gov/2699919/ (accessed on 10 October 2022).
  23. Liu, W.S.; Chung, Y.T.; Yang, C.Y.; Lin, C.C.; Tsai, K.H.; Yang, W.C.; Chen, T.W.; Lai, Y.T.; Li, S.Y.; Liu, T.Y. Serum creatinine determined by Jaffe, enzymatic method, and isotope dilution-liquid chromatography-mass spectrometry in patients under hemodialysis. J. Clin. Lab. Anal. 2012, 26, 206–214. Available online: https://pubmed.ncbi.nlm.nih.gov/22628238/ (accessed on 10 October 2022). [CrossRef]
  24. Karkkainen, P.; Poikolainen, K.; Salaspuro, M. Serum beta-hexosaminidase as a marker of heavy drinking. Alcohol. Clin. Exp. Res. 1990, 14, 187–190. Available online: https://pubmed.ncbi.nlm.nih.gov/1972003/ (accessed on 10 October 2022). [CrossRef]
  25. Waszkiewicz, N.; Szajda, S.D.; Jankowska, A.; Waszkiewicz, M.; Kepka, A.; Konarzewska, B.; Szulc, A.; Snarsk, J.; Zwierz, K. Catabolism of salivary glycoconjugates in acute ethanol intoxication. Med. Sci. Monit. 2009, 15, CR413–CR417. Available online: https://pubmed.ncbi.nlm.nih.gov/19644418/ (accessed on 10 October 2022).
  26. Markowski, T.; Ferens-Sieczkowska, M.; Zwierz, K.; Wojtulewska, A. Activity of N-acetyl-beta-hexosaminidase and gamma-glutamyltransferase in serum of alcohol addicted persons hospitalised after period of chronic drinking. Psychiatr. Pol. 2003, 37, 495–502. Available online: https://pubmed.ncbi.nlm.nih.gov/13677978/ (accessed on 10 October 2022).
  27. Stowell, L.; Stowell, L.; Garrett, N.; Robinson, G. Comparison of serum beta-hexosaminidase isoenzyme B activity with serum carbohydrate-deficient transferrin and other markers of alcohol abuse. Alcohol Alcohol. 1997, 32, 703–714. Available online: https://pubmed.ncbi.nlm.nih.gov/9463724/ (accessed on 10 October 2022). [CrossRef] [Green Version]
  28. Weissmann, G.; Smolen, J.E.; Korchak, H. Prostaglandins and inflammation: Receptor/cyclase coupling as an explanation of why PGEs and PGI2 inhibit functions of inflammatory cells. Adv. Prostaglandin Thromboxane Res. 1980, 8, 1637–1653. [Google Scholar]
  29. Belch, J.J.; Hill, A. Evening primrose oil and borage oil in rheumatologic conditions. Am. J. Clin. Nutr. 2000, 71 (Suppl. S1), 352S–356S. Available online: https://pubmed.ncbi.nlm.nih.gov/10617996/ (accessed on 10 October 2022).
  30. Bonta, I.L.; Parnham, M.J. Time-dependent stimulatory and inhibitory effects of prostaglandin E1 on exudative and tissue components of granulomatous inflammation in rats. Br. J. Pharmacol. 1979, 65, 465–472. Available online: https://pubmed.ncbi.nlm.nih.gov/427320/ (accessed on 10 October 2022). [CrossRef]
  31. Kepka, A.; Szajda, S.D.; Jankowska, A.; Waszkiewicz, N.; Chojnowska, S.; Zwierz, K. N-acetyl-beta-hexosaminidase- marker of the damage to the proximal renal tubules. Pol. Merk. Lek. 2008, 25, 288–290. Available online: https://pubmed.ncbi.nlm.nih.gov/19112852/ (accessed on 10 October 2022).
  32. Traczyk, W.Z.; Trzebski, A. Human Physiology With Elements of Applied And Clinical Physiology; PZWL: Warszawa, Poland, 1990; Available online: https://docer.pl/doc/xe1xs5c (accessed on 10 October 2022).
  33. Czartoryska, B. Lysosomal glycosidases in heteropolysaccharide catabolism (author’s transl). Postepy Biochem. 1977, 23, 229–266. Available online: https://pubmed.ncbi.nlm.nih.gov/876893/ (accessed on 10 October 2022).
  34. Roszczenko, A.; Gałazyn-Sidorczuk, M.; Brzóska, M.M.; Moniuszko-Jakoniuk, J.; Zwierz, K. Select parameters of renal function in smokers in correlation with the exposure to cadmium. Przegl. Lek. 2004, 61, 348–350. [Google Scholar]
  35. Basaranoglu, M.; Basaranoglu, G.; Senturk, H. From fatty liver to fibrosis: A tale of “second hit”. World J. Gastroenterol. 2013, 19, 1158–1165. Available online: https://pubmed.ncbi.nlm.nih.gov/23483818/ (accessed on 10 October 2022). [CrossRef]
  36. Phillips, M.; Curtis, H.; Portmann, B.; Donaldson, N.; Bomford, A.; O’Grady, J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis—Arandomised clinical trial. J. Hepatol. 2006, 44, 784–790. Available online: https://pubmed.ncbi.nlm.nih.gov/16469404/ (accessed on 10 October 2022). [CrossRef]
Ijerph 20 03413 g001 550
Figure 1. Variability over time in the concentration of serum HEX activity (nKat/L) of control group patients addicted to alcohol but not treated with neoglandin (K); *** p < 0.001.
Figure 1. Variability over time in the concentration of serum HEX activity (nKat/L) of control group patients addicted to alcohol but not treated with neoglandin (K); *** p < 0.001.
Ijerph 20 03413 g001
Ijerph 20 03413 g002 550
Figure 2. Variability over time in the concentration of serum HEX activity (nKat/L) of alcohol-dependent patients treated with neoglandin (N).
Figure 2. Variability over time in the concentration of serum HEX activity (nKat/L) of alcohol-dependent patients treated with neoglandin (N).
Ijerph 20 03413 g002
Ijerph 20 03413 g003 550
Figure 3. Serum HEX activity concentration (nKat/L) in patients addicted to alcohol and treated with neoglandin (N) compared to the control group patients (K) who were addicted to alcohol but not treated with neoglandin; * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 3. Serum HEX activity concentration (nKat/L) in patients addicted to alcohol and treated with neoglandin (N) compared to the control group patients (K) who were addicted to alcohol but not treated with neoglandin; * p < 0.05, ** p < 0.01, *** p < 0.001.
Ijerph 20 03413 g003
Ijerph 20 03413 g004 550
Figure 4. Variability over time in the concentration of urinary HEX activity (nKat/L) of control group patients addicted to alcohol but not treated with neoglandin (K); *** p < 0.001.
Figure 4. Variability over time in the concentration of urinary HEX activity (nKat/L) of control group patients addicted to alcohol but not treated with neoglandin (K); *** p < 0.001.
Ijerph 20 03413 g004
Ijerph 20 03413 g005 550
Figure 5. Variability over time in the concentration of urinary HEX activity (nKat/L) of alcohol-dependent patients treated with neoglandin (N).
Figure 5. Variability over time in the concentration of urinary HEX activity (nKat/L) of alcohol-dependent patients treated with neoglandin (N).
Ijerph 20 03413 g005
Ijerph 20 03413 g006 550
Figure 6. Urinary HEX activity concentration (nKat/L) in patients addicted to alcohol and treated with neoglandin (N) compared to the control group patients (K) who were addicted to alcohol but not treated with neoglandin; * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 6. Urinary HEX activity concentration (nKat/L) in patients addicted to alcohol and treated with neoglandin (N) compared to the control group patients (K) who were addicted to alcohol but not treated with neoglandin; * p < 0.05, ** p < 0.01, *** p < 0.001.
Ijerph 20 03413 g006
Ijerph 20 03413 g007 550
Figure 7. Urinary HEX specific activity (μKat/kg creatinine) of control group patients (K), in subjects who were addicted to alcohol but not treated with neoglandin; ** p < 0.01, *** p < 0.001.
Figure 7. Urinary HEX specific activity (μKat/kg creatinine) of control group patients (K), in subjects who were addicted to alcohol but not treated with neoglandin; ** p < 0.01, *** p < 0.001.
Ijerph 20 03413 g007
Ijerph 20 03413 g008 550
Figure 8. Variability over time of specific urinary HEX activity (μKat/kg creatinine) of alcohol-dependent patients treated with neoglandin (N).
Figure 8. Variability over time of specific urinary HEX activity (μKat/kg creatinine) of alcohol-dependent patients treated with neoglandin (N).
Ijerph 20 03413 g008
Ijerph 20 03413 g009 550
Figure 9. Specific urinary HEX activity (μKat/kg creatinine) in patients addicted to alcohol and treated with neoglandin (N) compared to the control group patients (K) who were addicted to alcohol but not treated with neoglandin; * p < 0.05; ** p < 0.01.
Figure 9. Specific urinary HEX activity (μKat/kg creatinine) in patients addicted to alcohol and treated with neoglandin (N) compared to the control group patients (K) who were addicted to alcohol but not treated with neoglandin; * p < 0.05; ** p < 0.01.
Ijerph 20 03413 g009
Table
Table 1. The concentration of serum HEX activity (nKat/L) in alcohol-dependent patients treated with neoglandin (N1–N30) and the control group not treated with neoglandin (K1–K30). Blood samples were collected on days 1, 4, 7, 10, 14 and 30 of hospitalization.
Table 1. The concentration of serum HEX activity (nKat/L) in alcohol-dependent patients treated with neoglandin (N1–N30) and the control group not treated with neoglandin (K1–K30). Blood samples were collected on days 1, 4, 7, 10, 14 and 30 of hospitalization.
Group SymbolsNAverage
x ¯ 		Median
Me		Standard Deviation
±SD		Probability of Random Differences
P
K150498.780402.000261.8580.065
N130396.233332.000162.800
K449380.327322.000163.7500.957
N431390.645352.000178.634
K748322.792284.000131.5780.022
N731367.742364.000124.861
K1041297.854272.000109.6490.006
N1029385.793368.000157.439
K1444283.182260.00077.2600.008
N1427355.704376.000130.419
K3038254.263243.00056.5520.000
N3023404.348368.000179.336
Table
Table 2. The concentration of urinary HEX activity (nKat/L) in alcohol-dependent patients treated with neoglandin (N1–N30) and the control group not treated with neoglandin (K1–K30). Urine samples were collected on days 1, 4, 7, 10, 14 and 30 of hospitalization.
Table 2. The concentration of urinary HEX activity (nKat/L) in alcohol-dependent patients treated with neoglandin (N1–N30) and the control group not treated with neoglandin (K1–K30). Urine samples were collected on days 1, 4, 7, 10, 14 and 30 of hospitalization.
Group SymbolsNAverage
x ¯ 		Median
Me		Standard Deviation
±SD		Probability of Random Differences
P
K147219.574170.000191.9160.000
N12990.75984.00059.319
K448158.000132.000113.1540.001
N43089.93373.00054.184
K746115.413120.00056.6580.056
N72790.59380.00057.710
K1040103.55094.00075.8410.013
N102769.11168.00038.239
K144288.85789.00035.1390.141
N142576.56064.00045.671
K303786.59588.00029.2450.013
N302165.61958.00037.649
Table
Table 3. The urinary activity of HEX (μKat/kg creatinine) in those addicted to alcohol treated with neoglandin (N1-N30) and the control group which was not treated with neoglandin (K1-K30). Urine samples were collected on days 1, 4, 7, 10, 14 and 30.
Table 3. The urinary activity of HEX (μKat/kg creatinine) in those addicted to alcohol treated with neoglandin (N1-N30) and the control group which was not treated with neoglandin (K1-K30). Urine samples were collected on days 1, 4, 7, 10, 14 and 30.
Group SymbolsNAverage
x ¯ 		Median
Me		Standard Deviation
±SD		Probability of Random Differences
P
K142204.791115.258242.7850.015
N128115.63262.164122.059
K443158.100114.286140.3300.003
N429108.13876.316116.101
K743134.585113.043102.7990.048
N726100.61374.60296.720
K1040109.30173.190106.2090.162
N102785.56558.33383.968
K143984.13474.46849.8980.782
N142382.30462.74548.212
K303774.15067.11446.3200.389
N302070.55447.58654.996
Table
Table 4. Correlations of variables in the urine of the control group.
Table 4. Correlations of variables in the urine of the control group.
CONTROL GROUP
nRP
URINE
Positive correlation
ALT d4/GGTP d4300.70.000
ALT d10/GGTP d10300.80.000
hex d1/creatinined1420.40.011
hex d4/creatinined4430.50.001
hex d7/creatinined7430.30.024
hex d14/creatinined14390.50.004
hex d30/creatinined30370.50.004
alcohol a day/hex d4480.40.009
alcohol a day/hex d10400.30.031
alcohol a day_kg/hex d4480.40.007
alc. per month/hex d4480.40.002
alc. per month/hex d7460.40.008
alc. per month/hex d10400.50.002
alc. per month/hex d14420.40.007
age/hex d1470.40.007
age/hexcw30370.30.038
age/hex_kg_creat. d7430.30.034
alc. per month/creat. d4430.30.029
alcohol a day/creat. d4430.30.036
alcohol a day_kg/creat. d4430.30.048
Negative correlations
Hexcw30/cerat. d3037−0.60.000
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Szajda, S.D.; Dobryniewski, J.; Minarowska, A.; Snarska, J.; Waszkiewicz, N.; Zwierz, K. The Effect of Neoglandin on the Activity of N-Acetyl-β-D-Hexosaminidase in the Serum and Urine of Alcohol-Dependent Men. Int. J. Environ. Res. Public Health 2023, 20, 3413. https://doi.org/10.3390/ijerph20043413

AMA Style

Szajda SD, Dobryniewski J, Minarowska A, Snarska J, Waszkiewicz N, Zwierz K. The Effect of Neoglandin on the Activity of N-Acetyl-β-D-Hexosaminidase in the Serum and Urine of Alcohol-Dependent Men. International Journal of Environmental Research and Public Health. 2023; 20(4):3413. https://doi.org/10.3390/ijerph20043413

Chicago/Turabian Style

Szajda, Sławomir Dariusz, Jacek Dobryniewski, Alina Minarowska, Jadwiga Snarska, Napoleon Waszkiewicz, and Krzysztof Zwierz. 2023. "The Effect of Neoglandin on the Activity of N-Acetyl-β-D-Hexosaminidase in the Serum and Urine of Alcohol-Dependent Men" International Journal of Environmental Research and Public Health 20, no. 4: 3413. https://doi.org/10.3390/ijerph20043413

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop